Sha Tan

Sha Tan

Auto-generated profile, based on publicly available information

Sha Tan

Multiple Sclerosis Center Department of Neurology The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
JWJingqi Wang
Jingqi Wang
CCChunping Cui
Chunping Cui
YLYaxin Lu
Yaxin Lu
YCYanyu Chang
Yanyu Chang
YWYuge Wang
Yuge Wang
STSha Tan
Sha Tan
Objective: To explore the outcomes of NMOSD attacks and investigate serum biomarkers for prognosis and severity.Method: Patients with NMOSD attacks were prospectively and observationally enrolled from January 2019 to December 2020 at four hospitals in Guangzhou, southern China. Data were collected at attack, discharge and 1/3/6 months after acute treatment. Serum cytokine/chemokine and neurofilament light chain (NfL) levels were examined at the onset stage.Results: One hundred patients with NMOSD attacks were included. The treatment comprised intravenous methylprednisolone pulse therapy alone (IVMP, 71%), IVMP combined with apheresis (8%), IVMP combined with intravenous immunoglobulin (18%) and other therapies (3%). EDSS scores decreased significantly from a medium of 4 (interquartile range 3.0–5.5) at attack to 3.5 (3.0–4.5) at discharge, 3.5 (2.0–4.0) at the 1-month visit and 3.0 (2.0–4.0) at the 3-month visit (p<0.01 in all comparisons). The remission rate was 38.0% at discharge and 63.3% at the 1-month visit. Notably, relapse occurred in 12.2% of 74 patients by the 6-month follow-up. Higher levels of T helper cell 2 (Th2)-related cytokines, including interleukin (IL)-4, IL-10, IL-13, and IL-1 receptor antagonist, predicted remission at the 1-month visit (OR=9.33, p=0.04). Serum NfL levels correlated positively with onset EDSS scores in acute-phase NMOSD (p<0.001, R2 = 0.487).Conclusions: Outcomes of NMOSD attacks were generally moderate. A high level of serum Th2-related cytokines predicted remission at the 1-month visit, and serum NfL may serve as a biomarker of disease severity at attack.Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04101058, identifier NCT04101058.

1 February 2018 in Neurochemistry International
Verified
Journal Article
Closed access
YLYinyao Lin
Yinyao Lin
STSha Tan
Sha Tan
YWYuge Wang
Yuge Wang
XSXianru Shen
Xianru Shen
YSYaqing Shu
Yaqing Shu
ZLZhengqi Lu
Zhengqi Lu

9 May 2019 in BMC Neurology
Verified
Journal Article
Open access
PDF file
XZXiaonan Zhong
Xiaonan Zhong
YCYanyu Chang
Yanyu Chang
STSha Tan
Sha Tan
JWJingqi Wang
Jingqi Wang
XSXiaobo Sun
Xiaobo Sun
WQWei Qiu
Wei Qiu
Recurrent optic neuritis (ON) was previously thought to be associated with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). Meningoencephalitis has recently been suggested to be a clinical finding typical of myelin oligodendrocyte glycoprotein (MOG) encephalomyelitis. We report a Chinese patient with recurrent ON at disease initiation, who had a delayed diagnosis of MOG-IgG syndrome, until recurrent meningoencephalitis appeared and serum MOG-IgG was detected. From the age of 7 years, an AQP4-IgG negative female patient had 10 disease recurrences, including 4 episodes of recurrent ON, 4 episodes of fever and meningoencephalitis, and 2 episodes of ON as well as meningoencephalitis. She was initially diagnosed as recurrent ON and treated with glucocorticoids followed by gradual tapering when ON reoccurred. Later, she was diagnosed as central nervous system infection when fever and meningoencephalitis appeared, and antiviral drugs and glucocorticoids were used. However, when she returned to our department for follow-up on July 2017, the results of serum demyelinating autoimmune antibody revealed positive MOG-IgG (titer 1:320 by an in-house, cell-based assay using live cells transfected with full-length human MOG). A diagnosis of MOG-IgG syndrome was established. Testing for MOG-IgG in atypical MS and NMOSD patients, and patients with meningoencephalitis with a history of relapsing demyelinating symptoms is warranted.

20 November 2022 in Journal of Neurochemistry
Verified
Journal Article
Closed access
YLYinyao Lin
Yinyao Lin
ZZZexin Zhan
Zexin Zhan
MHMengyan Hu
Mengyan Hu
HLHaiyan Li
Haiyan Li
BZBingjun Zhang
Bingjun Zhang
BQBing Qin
Bing Qin

6 September 2016 in BMC Neurology
Verified
Journal Article
Open access
PDF file
STSha Tan
Sha Tan
LZLei Zhang
Lei Zhang
XCXiaoyu Chen
Xiaoyu Chen
YWYanqiang Wang
Yanqiang Wang
YLYinyao Lin
Yinyao Lin
ZLZhengqi Lu
Zhengqi Lu
The underlying causes of minor stroke are difficult to assess. Here, we evaluate the reliability of the Chinese Ischemic Stroke Subclassification (CISS) system in patients with minor stroke, and compare it to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) system. A total of 320 patients with minor stroke were retrospectively registered and categorized into different subgroups of the CISS and TOAST by two neurologists. Inter- and intra-rater agreement with the two systems were assessed with kappa statistics. The percentage of undetermined etiology (UE) cases in the CISS system was 77.3 % less than that in the TOAST system, which was statistically significant (P < 0.001). The percentage of large artery atherosclerosis (LAA) in the CISS system was 79.7 % more than that in the TOAST system, which was also statistically significant (P < 0.001). The kappa values for inter-examiner agreement were 0.898 (P = 0.031) and 0.732 (P = 0.022) for the CISS and TOAST systems, respectively. The intra-observer reliability indexes were moderate (0.569 for neurologist A, and 0.487 for neurologist B). The CISS and TOAST systems are both reliable in classifying patients with minor stroke. CISS classified more patients into known etiologic categories without sacrificing reliability.

17 February 2023 in Journal of Neurochemistry
Verified
Journal Article
Closed access
FPFuhua Peng
Fuhua Peng
HSHongda She
Hongda She
YWYuge Wang
Yuge Wang
LXLi Xu
Li Xu
YSYilong Shan
Yilong Shan
STSha Tan
Sha Tan